Twitter profile of Cipla SA Facebook profile of Cipla SA Website of Cipla SA
 
Cipla SA
Dominic Uys
0626759529
dominic.uys@epicmslgroup.com
Ahlumile Mahlinza
0849563433
ahlumile.mahlinza@epicmslgroup.com
 

Debunking myths on probiotics - survey

 
Probiotics

Probiotics Survey

The 2016 Digestive Health Trends Index, commissioned by Cipla, was conducted among over 200 randomly selected consumers, and indicated that only 31% of South Africans are aware that three quarters of the immune system is located in the gut. This is only one of the many misconceptions South Africans have regarding digestive health, that were reflected by the survey results. All these misconceptions must be addressed to ensure that people have a better understanding of digestive health and the important role of probiotics.

The results indicated that there are several other myths that are commonly believed by many South Africans.

28% of the survey respondents indicated that they look at the number of strains in a product when selecting a probiotic. Many consumers think that a product containing many (for example up to 7 or more strains), is the most important element when selecting a probiotic. The gut has a limited surface area and binding sites for strains and as a result the various strains will compete for binding sites. Probiotic product selection should be about quality of gut coverage and not the quantity of strains.

Please see full media release below the infographic.

Proffessor Leon Dicks is keen to discuss the following:

  • Myth: surrounding the consumption of a probiotic in conjunction with an antibiotic
  • Myth: on specific amount of yogurt needed
  • Myth: on how effective Yeast is as compared to other sources of probiotic.
  • Potential benefits related to taking a probiotic vitamin.

Should you wish to have a chat with Proff Dicks, feel free to contact me and I will set it up for you gladly.

 

DEBUNKING MYTHS ON PROBIOTICS – SURVEY

The 2016 Digestive Health Trends Index, commissioned by Cipla, was conducted among over 200 randomly selected consumers, and indicated that only 31% of South Africans are aware that three quarters of the immune system is located in the gut. This is only one of the many misconceptions South Africans have regarding digestive health, that were reflected by the survey results. All these misconceptions must be addressed to ensure that people have a better understanding of digestive health and the important role of probiotics.

The results indicated that there are several other myths that are commonly believed by many South Africans.

Myth: Probiotics must only be taken in conjunction with antibiotics

According to the Cipla Digestive Health Trends Index 11% of South Africans believe that a probiotic must only be taken in conjunction with an antibiotic. Antibiotics destroy the good and the bad bacteria in the gut, which is why a dose of probiotics is necessary to replace the good bacteria. Probiotics do however have many benefits aside from this function, such as assisting with Irritable Bowels Syndrome (IBS), travellers’ diarrhoea and providing support for the immune system.

Myth: Yogurt is a sufficient probiotic

71% of South African consumers believe that consuming a daily serving of yogurt is a sufficient source of probiotic. The reality is that a person would need to consume a minimum of 40 liters of yogurt per day in order to meet the suggested daily probiotic quota for optimum digestive health. The minimum effective dose of probiotics is a 100-million colony forming units (CFU’s), i.e. 100-million viable cells. Another important measure is that the cells need to survive the harsh gastro-intestinal conditions, multiply and adhere to the gut wall.

Myth: Yeast is a more effective probiotic

Yeast are multicellular and more complex than bacterial cells. They require more nutrients to proliferate in the gut. The surface of yeast cells have less adhesion structures compared to probiotic bacterial cells and may not bind to the gut as effectively as bacteria.

Myth: The number of strains in a probiotic is the most important element

28% of the survey respondents indicated that they look at the number of strains in a product when selecting a probiotic. Many consumers think that a product containing many (for example up to 7 or more strains), is the most important element when selecting a probiotic. The gut has a limited surface area and binding sites for strains and as a result the various strains will compete for binding sites. Probiotic product selection should be about quality of gut coverage and not the quantity of strains.

What is meant by “quality of coverage”? Managing balance of intestinal flora in the entire gut is important. Choosing a probiotic which offers a combination of strains (even as little as 2) which is able to provide coverage of both the small- and large intestine is what counts.

There are numerous potential benefits related to taking a daily probiotic, a significant reason being the support provided to the immune system. It is therefore important to debunk these myths around probiotics and to ensure that South Africans are aware of the true benefits of taking daily probiotic.


 

Related Photos


 
 

Related Videos


 

Quotes & Related Information


 
71% of South African consumers believe that consuming a daily serving of yogurt is a sufficient source of probiotic. The reality is that a person would need to consume a minimum of 40 liters of yogurt per day in order to meet the suggested daily probiotic quota for optimum digestive health.
 

Related Links


 
 

Related Tweets


 
 

Share this Article


 
   
 

About Cipla:

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla’s turnover in FY 2013-14 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla’s research and development focuses on developing innovative products and drug delivery systems and has given India and the world many ‘firsts’ for instance Triomune. In a tightly regulated environment, the company’s manufacturing facilities have approvals from all the main regulators including US FDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

Clients